Company Profile

White Rock Therapeutics
Profile last edited on: 10/1/22      CAGE: 90BQ9      UEI: X74CWG22J461

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5223 Miller Avenue
Dallas, TX 75206
   (646) 286-1188
Location: Single
Congr. District: 32
County: Dallas

Public Profile

With the firm registered in Wyoming in 2021, but identified as in Dallas TX for its first SBIR Award with the actual work on the project indicated as being undertaken in the Downstate Biotechnology Incubator in Brooklyn NY, it is a little difficult to know how to assign White Rock Therapetics geographically. That noted, the areas of expertise of the firm's President and PI, organize around G-protein-coupled receptor (GPCR) signaling, biochemistry and pharmacology; Single-molecule FRET, Protein X-ray Crystallography, Structural Biology, Biochemistry, Molecular Biophysics

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 NSF $256,000
Project Title: Ace2 decoy as a pan-coronavirus therapeutic (COVID-19)

Key People / Management

  Gabriel Glenn Gregorio -- President

Company News

There are no news available.